Efficacy and Safety of Monthly 150 mg Oral Ibandronate in Women with Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Once-monthly oral ibandronate in postmenopausal osteoporosis: Translation and updated review

(2009) Maurizio Rossini et al.   CLINICAL THERAPEUTICS

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

(2009) Ronald Emkey et al.   CLINICAL THERAPEUTICS

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg

(2009) S. Epstein et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss

(2008) Michael R. McClung et al.   BONE

Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: Results of a meta-analysis

(2008) Anthony I. Sebba et al.   BONE

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension

(2008) Jacob A. Stakkestad et al.   CLINICAL RHEUMATOLOGY

Ibandronate

(2008) James E Frampton et al.   DRUGS

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II)

(2008) Peyman Hadji et al.   JOINT BONE SPINE

Once-Monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women with Postmenopausal Osteoporosis

(2008) E. Michael Lewiecki et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM